Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Income from Continuing Operations (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Income from Continuing Operations for 3 consecutive years, with 30060000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 26.46% to 30060000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 35527000.0 through Dec 2025, up 30.57% year-over-year, with the annual reading at 35514000.0 for FY2025, 30.48% up from the prior year.
  • Income from Continuing Operations hit 30060000.0 in Q4 2025 for Immunocore Holdings, down from 196000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 8693000.0 in Q3 2024 to a low of 30060000.0 in Q4 2025.
  • Historically, Income from Continuing Operations has averaged 11832250.0 across 3 years, with a median of 14315000.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: surged 859.49% in 2024 and later crashed 102.25% in 2025.
  • Year by year, Income from Continuing Operations stood at 19730000.0 in 2023, then fell by 20.48% to 23771000.0 in 2024, then dropped by 26.46% to 30060000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for IMCR at 30060000.0 in Q4 2025, 196000.0 in Q3 2025, and 10294000.0 in Q2 2025.